Pentagon-Backed Lumen is Ready to Drastically Slash Antibody Manufacturing Costs

Seattle-based Lumen Bioscience, led by CEO Brian Finrow, is developing a method to produce antibodies in edible spirulina, drastically lowering costs and enabling oral administration. Their LMN-201 treatment for C. difficile, funded by the Defense Department, is in Phase 3 trials. Lumen can reduce antibody production costs from $100–$200 per gram to around 10 cents, with potential for even cheaper production.